🔎 Trials Near Me

Home › Fibrolamellar hepatocellular carcinoma › Maryland

Fibrolamellar hepatocellular carcinoma clinical trials in Maryland

3 studies for Fibrolamellar hepatocellular carcinoma are looking for participants at sites in Maryland.

Cities in Maryland

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

  • Johns Hopkins SKCCC, Baltimore
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Oct 5, 2026 · NCT07430202

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

  • Johns Hopkins SKCCC, Baltimore
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Feb 12, 2026 · NCT06027086

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

  • Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Dec 3, 2025 · NCT04248569

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.